Ypsomed founds new subsidiary

(PresseBox) (Burgdorf, ) Ypsomed is establishing a new subsidiary in Austria. The signal for adding to the number of national subsidiary companies came with Ypsomed's participation in the annual conference of the Austrian Diabetes Association (ÖDG) from 17 to 19 November 2011 in Salzburg. By taking this expansionary step, the Burgdorf-based diabetes specialist intends to strengthen its mylife(TM) Diabetescare brand and continue on its path of growth.

The new Group company is based in Vienna and is led by Patrick Heil, who combines this role with that of General Manager for Switzerland. Simon Michel, Head of Marketing & Sales and member of the executive management of the Ypsomed Group, explains: 'There are a number of parallels between the Austrian and Swiss markets. Based on com-parable size, close distances and additionally the common german language are allowing synergies to be exploited in customer care and management.'

Market analysis suggests that the OmniPod® tube-free insulin patch pump has considerable market potential. The other products in the mylife(TM) range are also meeting with a high level of acceptance amongst diabetics and, in par-ticular, health insurance funds. 'Our expansion into Austria supports the Ypsomed Group as it undergoes a transfor-mation and will make a long-term contribution to the Group's future profitability', adds Simon Michel. mylife(TM) commercial products will be available on the Austrian market from 1 January 2012 onwards.

Ypsomed AG

The Ypsomed Group is a leading independent developer and manufacturer of injection systems for self-medication and a well-known diabetes specialist with more than 25 years' experience. The Ypsomed Group, which emerged in 2003 from the Disetronic Group, offers insulin pumps, injection systems and pen needles for diabetes, growth hor-mone and infertility treatments as well as for other therapeutic purposes. Ypsomed is an innovation and technology leader with an extensive patent portfolio and is the preferred partner of pharmaceutical and biotech companies in the self-medication sector. Ypsomed has established itself as a leading provider of brand, co-branding and OEM products in the retail and business-to-business segments. Ypsomed is also deeply committed to advances in patient care. Under the mylife(TM) Diabetescare brand, Ypsomed provides patients with the products it manufactures or distributes. The Ypsomed Group has its headquarters in Burgdorf, Switzerland. It has several manufacturing sites in Switzerland as well as leading independent diabetes product sales companies throughout Europe. The Ypsomed Group employs approximately 1,050 employees.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.


Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.